EVALUATION OF PHARMACOTHERAPY PROTOCOLS FOR COVID 19 PATIENTS IN BAQIYATALLAH HOSPITAL AND THEIR OUTCOMES
Ebrahimnegad, H., Boojar, M., Cheraghali, A., Shankayi, Z., Mohammadzadeh, T., Mirasheh, M., Poorhaji, M., Eidnezhad, M., Shahriari, M., Asadi, M., Amanpoor, H., Nikpouraghdam, M., Bahrami, F. (2021). EVALUATION OF PHARMACOTHERAPY PROTOCOLS FOR COVID 19 PATIENTS IN BAQIYATALLAH HOSPITAL AND THEIR OUTCOMES. EKB Journal Management System, 44(1), 89-97. doi: 10.21608/bfsa.2021.174134
Hami Reza Ebrahimnegad; Mahdi Mashhadi Akbar Boojar; Abdol Majid Cheraghali; Zeinab Shankayi; Tahereh Mohammadzadeh; Mohammad Hassan Mirasheh; Mohammad Mahdi Poorhaji; Mohammad Hosein Eidnezhad; Maryam Shahriari; Mohammad Mahdi Asadi; Hassan Amanpoor; Mohammad Nikpouraghdam; Farideh Bahrami. "EVALUATION OF PHARMACOTHERAPY PROTOCOLS FOR COVID 19 PATIENTS IN BAQIYATALLAH HOSPITAL AND THEIR OUTCOMES". EKB Journal Management System, 44, 1, 2021, 89-97. doi: 10.21608/bfsa.2021.174134
Ebrahimnegad, H., Boojar, M., Cheraghali, A., Shankayi, Z., Mohammadzadeh, T., Mirasheh, M., Poorhaji, M., Eidnezhad, M., Shahriari, M., Asadi, M., Amanpoor, H., Nikpouraghdam, M., Bahrami, F. (2021). 'EVALUATION OF PHARMACOTHERAPY PROTOCOLS FOR COVID 19 PATIENTS IN BAQIYATALLAH HOSPITAL AND THEIR OUTCOMES', EKB Journal Management System, 44(1), pp. 89-97. doi: 10.21608/bfsa.2021.174134
Ebrahimnegad, H., Boojar, M., Cheraghali, A., Shankayi, Z., Mohammadzadeh, T., Mirasheh, M., Poorhaji, M., Eidnezhad, M., Shahriari, M., Asadi, M., Amanpoor, H., Nikpouraghdam, M., Bahrami, F. EVALUATION OF PHARMACOTHERAPY PROTOCOLS FOR COVID 19 PATIENTS IN BAQIYATALLAH HOSPITAL AND THEIR OUTCOMES. EKB Journal Management System, 2021; 44(1): 89-97. doi: 10.21608/bfsa.2021.174134

EVALUATION OF PHARMACOTHERAPY PROTOCOLS FOR COVID 19 PATIENTS IN BAQIYATALLAH HOSPITAL AND THEIR OUTCOMES

Bulletin of Pharmaceutical Sciences Assiut University
Article 9, Volume 44, Issue 1, June 2021, Page 89-97  XML PDF (367.72 K)
Document Type: Original Article
DOI: 10.21608/bfsa.2021.174134
View on SCiNiTO View on SCiNiTO
Authors
Hami Reza Ebrahimnegad1; Mahdi Mashhadi Akbar Boojar2; Abdol Majid Cheraghali2; Zeinab Shankayi3; Tahereh Mohammadzadeh4; Mohammad Hassan Mirasheh1; Mohammad Mahdi Poorhaji1; Mohammad Hosein Eidnezhad1; Maryam Shahriari1; Mohammad Mahdi Asadi1; Hassan Amanpoor1; Mohammad Nikpouraghdam5; Farideh Bahrami3
1Students' Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran
2Department of Pharmacology and Toxicology, Faculty of Pharmacy, Baqiyatallah University of Medical Sciences, Tehran, Iran & Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
3Neuroscience Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran & Department of Physiology and Medical Physics, School of Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran
4Health and Nutrition Research Center, Baghiyatallah Medical Sciences University, Tehran, Iran
5Nephrology and Urology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
Abstract
Purpose: The propagation of the new coronavirus, COVID 19, is still a major priority for many countries around the world. Because of the lack of effective certain antiviral therapy for COVID 19. Special medicinal protocols are needed in medical centers to reduce the mortality rate. Methods: Due to constant change of national pharmacotherapy protocols for COVID-19 patients, this study compares the outcomes of three specific pharmacotherapy regimens (Table 1) and the combination of all 3 regimens for management of 614 COVID-19 patients hospitalized in Baqiyatallah hospital in Tehran, this hospital became a referral centers for receiving COVID 19 patients in Iran. Results: The more reliable result of treatments belongs to regimen 3 which indicated 98.26% recovered patients and 1.15% mortality rate and the lowest period of hospitalization with 4.4±0.21 days’ duration. Conclusion: It seems that regimen 3 (with a special combination of antiviral and Azithromycin ant anti-inflammatory drugs) had the best result in improving patients with COVID 19 and this result has not conflict with the comorbidity status of patients.
Statistics
Article View: 393
PDF Download: 381